Affiliation:
1. Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine; Novosibirsk State Medical University of Minzdrav of Russia
2. Novosibirsk State Medical University of Minzdrav of Russia
3. Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine
Abstract
Non-malignant breast diseases (NMBD) may increase the risk of developing a malignant neoplasm. Therefore, it seems relevant to search for criteria for cell malignancy in NMBD. Aim of the study was to investigate the relationship between expression of proliferation and epithelial-mesenchymal transition (EMT) markers and histidine-rich glycoprotein (HRG) mRNA in breast diseases. Material and methods. In breast biopsy specimens of 37 patients with invasive carcinoma of a non-specific type (ICNT) and 17 patients with NMBD expression of proliferation markers (Ki-67, cyclin D1 (CCND1)) and EMT markers (E-cadherin (CDH1), type II collagen (CII) and β1-integrin (CD29)) was determined immunohistochemically. HRG mRNA expression was estimated using real time PCR. Results. HRG mRNA expression was detected in 91.9 % cases (34 of 37) in ICNT, 82.4 % (14 of 17) in NMBD and in the latter case was inversely related to the expression of CDH1, CD29 and Ki-67. A direct relationship has been established between the presence of Ki-67 and CCND1, CII, between CCND1 and CD29 in NMBD. In patients with ICNT, a direct correlation was found between the HRG mRNA expression and the presence of CII, and an inverse correlation between the number of cells containing CII and CD29. It was found that in ICNT and NMBD with the presence of HRG mRNA expression, the CDH1 expression is less than in its absence. Conclusions. Indicators of HRG mRNA expression in NMBD, combined with the assessment of proliferation and EMT markers, can be useful in developing criteria for cell malignancy in benign breast diseases.
Publisher
Institute of Cytology and Genetics, SB RAS
Reference20 articles.
1. Liu H., Shi S., Gao J., Guo J., Li M., Wang L. Analysis of risk factors associated with breast cancer in women: a systematic review and meta-analysis. Transl. Cancer Res. 2022;11(5):1344–1353. doi: 10.21037/tcr22-193
2. Roman M., Louro J., Posso M., Vidal C., Bargallo X., Vazquez I., Quintana M., Alcantara R., Saladie F., Del Riego J., … On Behalf Of The Bele And Iris Study Groups. Long-term risk of breast cancer after diagnosis of benign breast disease by screening mammography. Int. J. Environ. Res. Public. Health. 2022;19(5):2625. doi: 10.3390/ijerph19052625
3. Kim S., Xuan T., Song H., Ryu S., Chang Y., Park B. Mammographic breast density, benign breast disease, and subsequent breast cancer risk in 3.9 million Korean women. Radiology. 2022;304(3):534–541. doi: 10.1148/radiol.212727
4. Salamat F., Niakan B., Keshtkar A., Rafiei E., Zendehdel M. Subtypes of benign breast disease as a risk factor of breast cancer: a systematic review and meta analyses. Iran. J. Med. Sci. 2018;43(4):355–364.
5. Posso M., Alcantara R., Vazquez I., Comerma L., Bare M., Louro J., Quintana M., Román M., MarcosGragera R., Vernet-Tomas M., … BELE study group. Mammographic features of benign breast lesions and risk of subsequent breast cancer in women attending breast cancer screening. Eur. Radiol. 2022;32(1):621– 629. doi: 10.1007/s00330-021-08118-y